Severe Hypertriglyceridemia
Synonyms
Hypertriglyceridemia, Chylomicronemia Syndrome,Overview
Severe hypertriglyceridemia (SHTG) is a metabolic disorder characterized by critically high levels of triglycerides in the blood, defined in most clinical guidelines as a fasting triglyceride level 500 mg/dL ( 5.7 mmol/L). It is distinct from mild-to-moderate hypertriglyceridemia because it presents a high risk for acute pancreatitis, a life-threatening, often, inflammatory condition of the pancreas.
Symptoms
Severe hypertriglyceridemia (typically defined as triglyceride levels >500 mg/dL, and especially >1,000–2,000 mg/dL) often presents no symptoms until levels are extremely high, at which point it can cause serious, life-threatening complications.
The most critical symptoms are related to acute pancreatitis and the accumulation of fat in organs and skin.
Causes
Severe hypertriglyceridemia (defined as fasting triglyceride levels >500 mg/dL, and especially >1000 mg/dL) is often caused by a combination of genetic predisposition and secondary lifestyle or medical factors, which together overwhelm the body’s ability to clear fat from the blood. The most critical risk associated with these high levels is acute pancreatitis.
Prevention
Severe hypertriglyceridemia (SHTG), typically defined as fasting triglyceride (TG) levels
500 mg/dL ( 5.6 mmol/L), requires immediate action to prevent acute pancreatitis, a life-threatening complication. The primary goal is to lower TG levels to below 500 mg/dL, with lifestyle modification—specifically diet and weight loss—serving as the cornerstone of therapy.
500 mg/dL ( 5.6 mmol/L), requires immediate action to prevent acute pancreatitis, a life-threatening complication. The primary goal is to lower TG levels to below 500 mg/dL, with lifestyle modification—specifically diet and weight loss—serving as the cornerstone of therapy.Diagnosis
Severe hypertriglyceridemia (SHTG) is characterized by extremely high levels of triglycerides in the blood, usually defined as serum triglyceride concentrations 500 mg/dL. While moderate levels (150–499 mg/dL) are primarily associated with cardiovascular risk, severe elevations (specifically
Prognosis
The prognosis is strongly linked to the risk of acute pancreatitis (AP), particularly when levels exceed. While high triglycerides are also associated with cardiovascular disease, the immediate threat in severe cases is pancreatic inflammation, which carries a significant morbidity rate.
Treatment
When TG levels exceed 1,000 mg/dL, immediate action is required to prevent acute pancreatitis:
- Intravenous (IV) Insulin/Heparin: Promotes rapid reduction of TG levels by activating lipoprotein lipase, often lowering them to safe levels within 2–3 days.
- Therapeutic Apheresis (Plasmapheresis): A highly effective method to acutely remove TGs from the blood in patients with severe pancreatitis or if insulin fails.
- Strict Dietary Fat Restriction: Immediate reduction of fat intake (less than 20-30 g/day) is necessary to reduce chylomicron production